← Eichor
Study identifier: NCT05080946 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Condition: Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer  ·  Sponsor: H. Lee Moffitt Cancer Center and Research Institute

PhaseEARLY_Phase 1
Planned participants100
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

This description comes directly from the study's public registry record.

Talk to the study team

Tiffany Shiles  ·  813-745-2948  ·  Tiffany.Shiles@moffitt.org

Always discuss trial participation with your own doctor first.

Locations (4)

Moffitt Cancer CenterTampa, Florida, United StatesRecruiting
Oregon Health and Science UniversityPortland, Oregon, United StatesRecruiting
University of Virginia Comprehensive Cancer CenterCharlottesville, Virginia, United StatesRecruiting
Inova Schar Cancer InstituteFairfax, Virginia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05080946